OTC Watch

All stocks / CYDY

CytoDyn Inc. CYDY

CytoDyn (CYDY): convertible notes mentioned in an 8-K in March 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

Estimated floatCostly financing OTCQBWashington, USA
Live quote on OTC Markets

Market listing

Full name
CYTODYN INC
Market tier
OTCQB
Trading status
Active
Last trade
Nov 16
Website
www.cytodyn.com
Source: Stockwatch, 2026-11-17

News headlines

CytoDyn Appoints Lauren Wilcoxen, Ph.D., as Chief Operating Officer and Head of Regulatory Affairs
2026-11-17 08:30 · News Release
CytoDyn Announces $5 Million Private Investment to Advance Leronlimab in Colorectal Cancer and Other Solid Tumors
2026-11-12 08:30 · News Release
CytoDyn and QLHC Advance Leronlimab into Two New PRE-I-SPY Studies in Metastatic Triple-Negative Breast Cancer
2026-11-10 08:30 · News Release
CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026
2026-10-26 08:30 · News Release
CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer
2026-10-19 16:50 · News Release
CytoDyn to Host Investor Webcast
2026-10-15 08:30 · News Release
CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026
2026-10-08 08:30 · News Release
CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th
2026-09-15 08:30 · News Release
CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab
2026-09-01 08:30 · News Release
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease
2026-06-11 08:30 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2026-05-31
The report says
Net loss
($42,699,000)
What it means

It spends more than it earns

Under strain

The company lost $42.7 million in the year. It reported no sales.

The report says
Cash and cash equivalents
$11,852,000
Net cash used in operating activities
($17,252,000)
What it means

The cash could run out soon

Under strain

It had $11.9 million in the bank and used about $1.4 million a month. At that pace the money lasts about 8 months unless it borrows or sells more shares.

The report says
Total assets
$13,973,000
Total liabilities
$123,691,000
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $14 million. Its debts and unpaid bills add up to $123.7 million. That is about $8.85 owed for every $1 owned.

What this adds up to

3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Estimated float2026-09-30

Estimated float about 1,469,518,000 shares as of 2026-09-30: 1,469,518,000 outstanding minus 0 held by 0 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Costly financing2026-03-24

8-K filed 2026-03-24 mentions: convertible note.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Costly financing2026-03-05

8-K filed 2026-03-05 mentions: convertible note, equity line.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Shares outstanding

Source: SEC filings
2025-11-30
1.27B
2025-12-31
1.27B
2026-02-28
1.36B
2026-03-31
1.37B
2026-05-31
1.37B
2026-06-30
1.38B
2026-08-31
1.45B
2026-09-30
1.47B

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-10-20 44
2026-10-19 8-K8-K
2026-10-19 DEFA14ADEFA14A
2026-10-14 10-Q10-Q
2026-10-07 424B3424B3
2026-10-07 EFFECT
2026-10-02 EFFECT
2026-10-02 EFFECT
2026-09-28 DEF 14ADEF 14A
2026-09-25 POS AMPOS AM
2026-09-25 POS AMPOS AM
2026-09-25 S-3S-3

Common questions about CYDY

Does CYDY file reports with the SEC?

Yes. CytoDyn files with the SEC under company number 0001175680. The most recent filing we hold is a 4 dated 2026-10-20.

Source record

How many CYDY shares are outstanding?

1,469,518,000 shares as of 2026-09-30, as reported to the SEC.

Source record

Has CYDY filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Who runs CytoDyn?

Officers named in its insider filings: Tyler Blok (Chief Legal Officer), Robert E. Hoffman (Chief Executive Officer) and Jacob P Lalezari (Chief Executive Officer).

Source record

Is CytoDyn making money?

The company lost $42.7 million in the year. It reported no sales. (Annual figures to 2026-05-31. Facts from the company's own report, not a recommendation.)

Source record